Skip to main content

Advertisement

SpringerLink
Log in

The interaction of Wnt-11 and signalling cascades in prostate cancer

  • Review
  • Published:
Tumor Biology

Abstract

Prostate cancer (PCa) is the second most common cancer among the male population. Conventional therapies target androgen signalling, which drives tumour growth; however, they provide limited survival benefits for patients. It is essential, therefore, to develop a more specific biomarker than the current gold standard, PSA testing. The Wnt signalling pathway induces expression of target genes through cell surface receptors. A non-canonical member of this family, Wnt-11, is evolutionarily highly conserved and is normally expressed by various cells in the developing embryo, as well as in the heart, liver and skeletal muscle of adult humans. We comprehensively review several cell signalling pathways to explain how they interact with Wnt-11, demonstrating its use as a potential biomarker for PCa. Several studies have shown that the expression of Wnt-11 is associated with gastric, renal and colorectal adenocarcinomas and PCa. Moreover, Wnt-11 affects extracellular matrix composition and cytoskeletal rearrangement, and it is required for proliferation and/or survival during cell differentiation. It was found that PCa cell lines express high levels of Wnt-11, which allows differentiation of the epithelial prostate tumour cells to neuron-like (NE) cells. The NE cells produce additional factors that can cause regression after treatment. Accumulating evidence shows that Wnt-11 could be a potential biomarker in diagnosing PCa. Many studies have shown both non-canonical and canonical Wnts interact with several signalling cascades such as PKC, JNK, NF-κB, Rho, PKA and PI3K. In particular, evidence demonstrates Wnt-11 is involved in the progression of PCa, thus it could have the potential to become both a specific disease marker and an important therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ (Clinical research ed). 2013;346:f325.

    Google Scholar 

  2. Cary K, Cooperberg M. Biomarkers in prostate cancer surveillance and screening: past, present and future. Ther Adv Urol. 2013;5(6):318–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009;60:139–51.

    Article  CAS  PubMed  Google Scholar 

  4. Bjurlin M, Loeb S. PSA velocity in risk stratification of prostate cancer. Rev Urol. 2013;15(4):204–6.

    PubMed  PubMed Central  Google Scholar 

  5. Hagglof C, Hammarsten P, Stromvall K, Egevad L, Josefsson A, Stattin P. TMPRSS2-ERG expression predicts prostate cancer survival and associated with stromal biomarkers. PLoS One. 2014;9(2):e86824.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hausmann G, Banziger C, Basler K. Helping wingless take flight: how WNT proteins are secreted. Nat Rev Mol Cell Biol. 2007;8(4):331–6.

    Article  CAS  PubMed  Google Scholar 

  7. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68–75.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol. 2010;2(2):a002915.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wang Y. Wnt/planar cell polarity signalling: a new paradigm for cance therapy. Mol Cancer Ther. 2009;8(8):2103–9.

    Article  CAS  PubMed  Google Scholar 

  10. Schlessinger K, Hall A, Tolwinski N. Wnt signalling pathways meet Rho GTPases. Genes Dev. 2009;23:265–77.

    Article  CAS  PubMed  Google Scholar 

  11. Kypta RM, Waxman J. Wnt/B-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9:418–28.

    Article  CAS  PubMed  Google Scholar 

  12. Uysal-Onganer P, Kypta RM. Wnt11 in 2011—the regulation and function of a non-canonical Wnt. Acta Physiol. 2012;204(1):52–64.

    Article  CAS  Google Scholar 

  13. Zhu H, Mazor M, Kawano Y. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res. 2004;64(21):7918–26.

    Article  CAS  PubMed  Google Scholar 

  14. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res. 2009;1(2):148–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer. 2010;9:55.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Newton A. Protein Kinase C: poised to signal. Am J Phsiol Endocrinol Metab. 2010;298(3).

  17. Garg R, Blando J, Perez C, Wang H, Benavides F, Kazaniez M. Activation of nuclear factor kB (NF-kB) in prostate cancer is mediated by protein kinase C ε (PKCε). J Biol Chem. 2012;287(44):37570–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Luna-Ulloa L, Hernandez-Maqueda J, Castaneda-Patlan M, Robles-Flores M. Protein Kinase C in Wnt signalling: implications in cancer initiation and progression. IUBMB Life. 63(10):915–21.

  19. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.

    Article  CAS  PubMed  Google Scholar 

  20. Saadeddin A, Babaei-Jadidi R, Spencer-Dene B, Nateri A. The links between transcription, beta-catenin/JNK signalling, and carcinogenesis. Mol Cancer Res. 2009;7(8):1189–96.

    Article  CAS  PubMed  Google Scholar 

  21. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009;19(1):71–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ma J, Zhang L, Han W, Shen T, Ma C, Liu Y, et al. Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells. J Lipid Res. 2012;53(6):1093–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog. 2007;46(8):591–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kunsch C, Rosen C. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol. 1993;13(10):6137–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Spencer G, Utting J, Etheridge S, Arnett T, Genever P. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFKappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119(9):1283–96.

    Article  CAS  PubMed  Google Scholar 

  26. Modder UI, Oursler MJ, Khosla S, Monroe DG. Wnt10b activates the Wnt, notch, and NFkappaB pathways in U2OS osteosarcoma cells. J Cell Biochem. 2011;112(5):1392–402.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lawrence T. The nuclear factor NK-kB pathway in inflammation. Inflammation. 2009:1–10.

  28. Taylor S, Beuchler J, Yonemoto W. cAMP-dependent protein kinase:framework for a diverse family of regulatory enzymes. Annu.Rev.Biochem. 1990;59:971–1005.

    Article  CAS  PubMed  Google Scholar 

  29. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010;11(1):9–22.

    Article  CAS  PubMed  Google Scholar 

  30. Sarwar M, Persson JL. The protein kinase A (PKA) intracellular pathway and androgen receptor: a novel mechanism underlying the castration-resistant and metastatic prostate cancer. J Cancer Sci & Ther. 2012;01(S5).

  31. Khor L, Bae K, Paulus R. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer. J Clin Oncol. 2009;27(19).

  32. Kim C, Xuong N, Taylor S. Crystal structure of a complex. Sci Mag. 2005;307:690–6.

    CAS  Google Scholar 

  33. Sainz R, Mayo J, Tan D, Len J, Manchester L, Resiter R. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005;63(1):29–75.

    Article  CAS  PubMed  Google Scholar 

  34. Shen R, Dorai T, Olsson C, Buttyan R, Katz A, Szaboles M. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol. 1997;3(2):67–75.

    Article  CAS  PubMed  Google Scholar 

  35. Caretta A, Caretta C. Protein kinase A in cancer. Cancer. 2011;3(1):913–26.

    Article  CAS  Google Scholar 

  36. Gallegos TF, Kouznetsova V, Kudlicka K, Sweeney DE, Bush KT, Willert K, et al. A protein kinase A and Wnt-dependent network regulating an intermediate stage in epithelial tubulogenesis during kidney development. Dev Biol. 2012;364(1):11–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ridley AJ. Rho GTPases and cell migration. J Cell Sci. 2001;114(15):2713–22.

    CAS  PubMed  Google Scholar 

  38. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett. 2008;582(14):2093–101.

    Article  CAS  PubMed  Google Scholar 

  39. Kusama T, Mukai M, Endo T, Ishikawa O, Tatsuta M, Nakamura H, et al. Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis. Cancer Sci. 2006;97(9):848–53.

    Article  CAS  PubMed  Google Scholar 

  40. Rathinam R, Berrier A, Alahari S. Role of Rho GTPases and their regulations in cancer progression. Front Biosci. 2011:2561–71.

  41. Fernandez-Borja M, Janssen L, Verwoerd D, Horijk P, Neefjes J. RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1. J Cell Sci. 2005;118(12):2661–70.

    Article  CAS  PubMed  Google Scholar 

  42. Huang M, Prendergast G. RhoB in cancer suppression. Histol Histopathol. 2006;21(1):213–8.

    CAS  PubMed  Google Scholar 

  43. Lui M, Tang Q, Qui M, Lang N, Li M, Zheng Y, et al. miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells. FEBS Lett. 2011;585(19):2998–3005.

    Article  Google Scholar 

  44. Wheeler AP, Ridley AJ. RhoB affects macrophage adhesion, integrin expression and migration. Exp Cell Res. 2007;313(16):3505–16.

    Article  CAS  PubMed  Google Scholar 

  45. Vega FM, Thomas M, Reymond N, Ridley AJ. The Rho GTPase RhoB regulates cadherin expression and epithelial cell-cell interaction. Cell Commun Signal. 2015;13:6.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;5(15):4799–805.

  47. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. 2010;115(3):559–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Majumder P, Sllers W. AKt-regulated pathways in prostate cancer. Oncogene. 2005;24(50):7465–74.

    Article  CAS  PubMed  Google Scholar 

  49. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr-Relat Cancer. 2013;20(3):R83–99.

    Article  CAS  PubMed  Google Scholar 

  50. Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.

    Article  CAS  PubMed  Google Scholar 

  51. Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41(5):619–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–92.

    Article  CAS  PubMed  Google Scholar 

  53. Staal FJT, Sen JM. The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol. 2008;38(7):1788–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab. 2010;21(12):707–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiff China Medical Research Collaborative, Institute of Cancer and Genetics, Cardiff University Henry Wellcome Building, Heath Park, CF14 4XN, UK

    Sarah Koushyar

  2. Department of Life Sciences, University of Bedfordshire, Park Square, Luton, LU1 3JU, UK

    Guy H. Grant

  3. Department of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, 115 New Cavendish Street, London, W1W 6UW, UK

    Pinar Uysal-Onganer

Authors
  1. Sarah Koushyar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guy H. Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pinar Uysal-Onganer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pinar Uysal-Onganer.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koushyar, S., Grant, G.H. & Uysal-Onganer, P. The interaction of Wnt-11 and signalling cascades in prostate cancer. Tumor Biol. 37, 13049–13057 (2016). https://doi.org/10.1007/s13277-016-5263-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5263-z

Keywords

Search

Navigation